(Total Views: 520)
Posted On: 02/21/2021 10:31:54 AM
Post# of 153869
Not worried - cd-12 was a designed FDA phase 3 trial when
CYDY hits primary endpoint it has to be approved no if ands or buts. If it doesn’t hit primary endpoint as long as it can show benefit over risk on primary or any secondary endpoints it should receive EUA and I think prob of that it’s higher than 95%.
CYDY hits primary endpoint it has to be approved no if ands or buts. If it doesn’t hit primary endpoint as long as it can show benefit over risk on primary or any secondary endpoints it should receive EUA and I think prob of that it’s higher than 95%.
(4)
(0)
